Introduction {#Sec1}
============

Despite advances in the treatment of breast cancer and an encouraging 5-year overall survival rate of approximately 90% in the United States, up to 30% of patients with an early-stage diagnosis eventually progress to incurable metastatic disease, and 6% of patients have metastatic disease at diagnosis \[[@CR1], [@CR2]\]. Treatment of metastatic breast cancer (MBC) is based on molecular subtype and may include chemotherapy, human epidermal growth factor receptor 2 (HER2)-directed agents, and endocrine-based therapies or agents targeted to mechanistic target of rapamycin or CDK4/6 for those tumors overexpressing estrogen receptor (ER) and/or progesterone receptor (PR) \[[@CR3]\]. Approximately, 15--20% of patients have breast cancers lacking expression of ER, PR, or HER2, which are termed triple-negative breast cancer (TNBC). For these patients, standard treatment is cytotoxic chemotherapy, which is limited by poor tolerability and short duration of response \[[@CR4]--[@CR6]\]. Thus, new therapies are needed for patients with MBC whose disease has progressed following standard therapies.

Immune checkpoint inhibitors, particularly agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1), are being increasingly explored as a potential treatment strategy in various cancers \[[@CR7]\]. Breast cancers express PD-L1, with higher expression often seen in TNBC tumors \[[@CR8]--[@CR10]\]. Binding of PD-L1 to its receptor on T cells, PD-1, inhibits adaptive immune responses in the tumor microenvironment, which enables tumor cell escape from immune cells \[[@CR11]--[@CR13]\]. The presence of tumor-infiltrating lymphocytes (TILs) in breast cancer has been shown to have a strong prognostic association \[[@CR14]\]. High TIL levels are associated with tumors having PD-L1 expression, and PD-L1+ tumors with high TILs have better outcomes \[[@CR9], [@CR10], [@CR15]\]. PD-L1 expression may serve as a marker of immune activity, and local immunosuppression of TILs via the PD-L1/PD-1 pathway may be an important means of tumor immune evasion \[[@CR8], [@CR14]\]. Inhibition of the PD-L1/PD-1 axis with monoclonal antibodies may be one means of restoring immune surveillance and cell-mediated antitumor activity, and studies of anti-PD-L1/PD-1 agents have shown durable antitumor responses in patients with various advanced cancers \[[@CR7], [@CR16]\]. Early-phase studies have suggested that these agents may also have clinical activity in breast cancer, particularly in the TNBC subtype \[[@CR17]--[@CR19]\].

Avelumab (MSB0010718C) is a human anti-PD-L1 IgG1 monoclonal antibody that inhibits the interaction between PD-1 and PD-L1, leaving PD-1/PD-L2 interactions intact \[[@CR20]\]. Unlike other anti-PD-L1/PD-1 antibodies approved or in advanced clinical development, avelumab has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells in preclinical studies, suggesting it may potentially have an additional mechanism of action \[[@CR21]--[@CR23]\]. In phases 1 and 2 clinical studies, avelumab has been well tolerated and associated with durable responses in patients with various advanced tumors, including Merkel cell carcinoma (MCC), non-small cell lung cancer, and urothelial carcinoma \[[@CR20], [@CR24]--[@CR26]\]. Avelumab is approved by the US Food and Drug Administration for the treatment of metastatic MCC and locally advanced or metastatic urothelial carcinoma that has progressed during or after platinum-containing chemotherapy \[[@CR27]\]. In the phase 1a part of the JAVELIN Solid Tumor study, avelumab was safely administered by intravenous infusion every 2 weeks and had a predictable pharmacokinetic profile at doses of up to 20 mg/kg; the 10 mg/kg dose was selected for further study in phase 1b dose-expansion cohorts enrolling a range of tumor types \[[@CR20]\]. Here, we report the evaluation of avelumab in a phase 1b cohort of patients with MBC as part of the JAVELIN Solid Tumor trial.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

JAVELIN Solid Tumor is an international, open-label, phase 1 trial in patients with advanced solid malignancies. In the dose-expansion cohort reported here, eligible patients had histologically confirmed locally advanced or MBC that was refractory to or had progressed after standard-of-care therapy. Eligible patients were aged ≥ 18 years and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, an estimated life expectancy of \> 3 months, and adequate hepatic, renal, and hematologic function. Patients had received ≤ 3 prior lines of cytotoxic therapy (excluding systemic therapy that was not considered cytotoxic) and, unless contraindicated, were required to have received prior treatment with a taxane and anthracycline in any therapeutic setting. Patients had ≥ 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 \[[@CR28]\]. A biopsy or surgical specimen for biomarker testing collected within 90 days prior to the first avelumab administration was required. Patients were unselected for PD-L1 expression and breast cancer subtype. Patients were enrolled in accordance with an approved protocol, international standards of good clinical practice, and institutional safety monitoring, and written informed consent was provided by patients.

Procedures and assessments {#Sec4}
--------------------------

Patients received avelumab (EMD Serono, Research & Development Institute, Billerica, MD, USA, a business of Merck KGaA, Darmstadt, Germany) 10 mg/kg intravenously every 2 weeks until confirmed disease progression, unacceptable toxicity, or other protocol-based criteria for withdrawal occurred. Safety and tolerability were assessed per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. Potential immune-related adverse events (AEs) were identified using a prespecified list of Medical Dictionary for Regulatory Activities terms. Signs and symptoms of an infusion-related reaction, such as fever, chills, or rigors reported on the same day or the day following treatment, were queried with investigators to ascertain whether an AE of infusion-related reaction should be recorded. Premedication with diphenhydramine and acetaminophen was required 30--60 min before all infusions of avelumab to mitigate the occurrence of infusion-related reactions. Tumors were evaluated radiographically at baseline and every 6 weeks for the first 12 months, then every 12 weeks thereafter. Best overall response, duration of response, and progression-free survival were determined according to RECIST version 1.1 per investigator.

HER2, ER, and PR statuses were obtained from patient records. Levels of PD-L1 protein expressed on tumor cell membranes and on membranes and/or cytoplasm of immune cells within the tumor microenvironment were assessed by immunohistochemistry (IHC) staining of formalin-fixed, paraffin-embedded tissue sections of the most recent suitable biopsy or surgical specimen using a proprietary assay (PD-L1 IHC 73-10 pharmDx; Dako, Carpinteria, CA, USA) with an anti-PD-L1 rabbit monoclonal antibody. PD-L1 expression was assessed prospectively by central independent reviewers, who were blinded to any clinical data; expression was based on the percentages of tumor cells expressing PD-L1: 1 and 5% thresholds with any staining intensity and a 25% threshold with moderate to high staining. Additionally, dense aggregates of tumor-associated immune cells (identified as nonmalignant cells based on morphology) adjacent to tumor cells were assayed using a defined threshold of 10% of immune cells expressing PD-L1 at any staining intensity.

Statistical methods {#Sec5}
-------------------

Enrollment of approximately 150 patients was planned for this cohort, and safety and activity were analyzed in all patients who received ≥ 1 dose of avelumab. The prespecified primary analysis occurred 6 months after the date of the first dose in the last patient enrolled. The objective response rate (ORR), defined as the proportion of patients with a confirmed best response of complete or partial response, was calculated with corresponding Clopper--Pearson CIs. Time-to-event endpoints (duration of response, progression-free survival, and overall survival) were estimated using Kaplan--Meier method, and CIs for the median were determined using the Brookmeyer--Crowley method. The trial is registered with ClinicalTrials.gov as NCT01772004.

Results {#Sec6}
=======

Patients {#Sec7}
--------

Of 266 patients screened, 168 patients with histologically confirmed MBC refractory to or progressing after standard-of-care therapy were enrolled and treated with avelumab between November 2013 and February 2015 (Table [1](#Tab1){ref-type="table"}, Appendix Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). Of these 168 patients, 26 patients (15.5%) had HER2-positive disease (irrespective of ER and PR status), 72 patients (42.9%) had hormone-receptor-positive/HER2-negative disease, and 58 patients (34.5%) had TNBC. Median age was 55 (range 31--81) years. Patients had received a median of three prior therapies for metastatic disease, and 123 patients (73.2%) had received ≥ 2 prior anticancer regimens for metastatic or locally advanced disease (Table [1](#Tab1){ref-type="table"}; Appendix Tables [4](#Tab4){ref-type="table"}, [6](#Tab6){ref-type="table"}). Median time since diagnosis of metastatic disease was 22 months (range 3 weeks to \> 14.7 years). Of 58 patients with TNBC, 50% had received ≥ 2 prior lines of therapy for metastatic disease and median time since diagnosis was 13 months. Tumor specimens were evaluable for PD-L1 expression in 136 patients (81.0%), and based on a threshold of ≥ 1% tumor cell staining, 85 of 136 (62.5%) had PD-L1+ tumors. Using a ≥ 10% threshold for PD-L1 expression in tumor-associated immune cells, 12 of 136 evaluable patients (8.8%) had PD-L1+ tumors.Table 1Selected baseline characteristicsCharacteristicsTotal population *N* = 168TNBC subgroup (*n* = 58)Median age, years (range)55 (31--81)52.5 (31--80)Age category, *n* (%) (years) \< 65140 (83.3)54 (93.1) ≥ 6528 (16.7)4 (6.9)Sex, *n* (%) Male1 (0.6)0 Female167 (99.4)58 (100)Race or ethnic group, *n* (%) White143 (85.1)45 (7.8) Black or African American16 (9.5)9 (15.5) Asian3 (1.8)1 (1.7) Other6 (3.6)3 (5.2)Geographic region, *n* (%) United States112 (66.7)48 (82.8) Europe56 (33.3)10 (17.2)ECOG PS, *n* (%) 083 (49.4)33 (56.9) 185 (50.6)25 (43.1)Smoking history, *n* (%) Never smoker107 (63.7)36 (62.1) Current or former smoker50 (29.8)17 (29.3) Unknown11 (6.5)5 (8.6)Histological subtype of tumor, *n* (%) Ductal94 (56.0)36 (62.1) Lobular6 (3.6)0 Carcinoma, not otherwise specified14 (8.3)6 (10.3) Other^a^54 (32.1)16 (27.6)Molecular subtype, *n* (%) TNBC58 (34.5)58 (100) HER2−/ER+ or PR+72 (42.9)-- HER2+26 (15.5)-- Unknown^b^12 (7.1)--Median time since first diagnosis, months (range)53.5 (7.3--407.5)40.3 (7.3--241.0)Median time since diagnosis of metastatic disease, months (range)^c^21.6 (0.7--176.8)13.2 (0.7--176.8)Prior anticancer lines of therapy for metastatic or locally advanced disease, *n* (%)^d^ ≤ 145 (26.8)29 (50.0) 235 (20.8)16 (27.6) ≥ 388 (52.4)13 (22.4) Median (range)3 (0--10)2 (1--6)PD-L1 expression status, *n*/*N* (%)^e^PD-L1+PD-L1−PD-L1+PD-L1−≥ 1% tumor cells85/136 (62.5)51/136 (37.5)33/48 (68.8)15/48 (31.2)≥ 5% tumor cells23/136 (16.9)113/136 (83.1)13/48 (27.1)35/48 (72.9)≥ 25% tumor cells3/136 (2.2)133/136 (97.8)2/48 (4.2)46/48 (95.8)≥ 10% tumor-associated immune cells12/136 (8.8)124/136 (91.2)9/48 (18.8)39/48 (81.2)*ECOG PS* Eastern Cooperative Oncology Group performance status, *ER* estrogen receptor, *HER2* human epidermal growth factor receptor 2, *PD*-*L1* programmed death-ligand 1, *PR* progesterone receptor, *TNBC* triple-negative breast cancer^a^Patients who were uncoded (overall, 41; TNBC, 11), other histology (overall, 10; TNBC, 5), or missing (overall, 3)^b^Unknown molecular subtype was due to incomplete information in the medical records database (ER/PR status known, but HER2 status unknown in four patients) or to information collected retrospectively (molecular subtype status was from post-baseline samples in eight patients and therefore was not used for baseline characterization)^c^Time since diagnosis of metastatic disease was missing for eight patients in the overall study population and six patients in the TNBC subgroup^d^Regimen for metastatic disease may have included hormonal therapy, either alone or in combination with chemotherapy. Systemic therapies that were not necessarily cytotoxic are included in the number of prior regimens reported here, but the number of prior cytotoxic therapies permitted was ≤ 3^e^Non-evaluable specimens included those that were missing, of poor quality or quantity (insufficient tissue on slide or insufficient tumor sample), or otherwise not available to provide results; all biopsy or surgical specimens were required to be collected within 90 days of first administration of avelumab

At the time of data cutoff (February 27, 2015), patients had received a median of four avelumab (range 1--23) doses and had a median treatment duration of 8.0 (range 2--50) weeks. Median duration of follow-up was 10.0 (range 6.0--15.2) months, and nine patients (5.4%) remained on avelumab treatment at data cutoff. Disease progression was the most common reason for treatment discontinuation (74.4%).

Safety {#Sec8}
------

Treatment-related AEs of any grade occurred in 115 patients (68.5%), including a grade ≥ 3 event in 23 patients (13.7%; Table [2](#Tab2){ref-type="table"}; Appendix Table [7](#Tab7){ref-type="table"}). The most commonly occurring treatment-related AEs of any grade (\> 10% of patients) were fatigue (19.0%), infusion-related reaction (14.3%), and nausea (13.1%). Treatment-related AEs of any grade classified as immune-related occurred in 17 patients (10.1%): hypothyroidism (4.8%), autoimmune hepatitis and pneumonitis (1.8% each), thrombocytopenia (1.2%), and antinuclear antibody production, dry eye, elevated rheumatoid factor, hyperthyroidism, and pemphigoid skin reaction (0.6% each; Appendix Table [8](#Tab8){ref-type="table"}). Four patients (2.4%) had a grade ≥ 3 immune-related, treatment-related AE (Appendix Table [8](#Tab8){ref-type="table"}), including three patients (1.8%) with grade 3 autoimmune hepatitis and one patient each with grade 3 pneumonitis and grade 4 thrombocytopenia (0.6% each). One patient with autoimmune hepatitis who had progressive liver metastasis died of acute liver failure.Table 2Treatment-related adverse events occurring at any grade in ≥ 5% of patients or grade ≥ 3 in any patient*N* = 168Any gradeGrades 1--2Grade 3Grade 4Grade 5Any event, *n* (%)115 (68.5)92 (54.8)16 (9.5)5 (3.0)2 (1.2) Fatigue32.9 (19.0)29 (17.3)3 (1.8)00 Infusion-related reaction24 (14.3)24 (14.3)000 Nausea22 (13.1)22 (13.1)000 Diarrhea15 (8.9)15 (8.9)000 Arthralgia13 (7.7)12 (7.1)1 (0.6)00 Decreased appetite12 (7.1)12 (7.1)000 Influenza-like illness11 (6.5)11 (6.5)000 Dyspnea exertional5 (3.0)4 (2.4)1 (0.6)00 Elevated AST4 (2.4)3 (1.8)1 (0.6)00 Elevated GGT4 (2.4)1 (0.6)1 (0.6)2 (1.2)0 Anemia3 (1.8)02 (1.2)1 (0.6)0 Autoimmune hepatitis3 (1.8)03 (1.8)00 Elevated ALT3 (1.8)2 (1.2)1 (0.6)00 Hypoxia3 (1.8)2 (1.2)1 (0.6)00 Pneumonitis3 (1.8)2 (1.2)1 (0.6)00 Axillary pain2 (1.2)1 (0.6)1 (0.6)00 Thrombocytopenia2 (1.2)1 (0.6)01 (0.6)0 Acute hepatic failure1 (0.6)0001 (0.6) Cardiac arrest1 (0.6)001 (0.6)0 Hypertriglyceridemia1 (0.6)01 (0.6)00 Hypokalemia1 (0.6)001 (0.6)0 Neutropenia1 (0.6)001 (0.6)0 Neutrophil count decreased1 (0.6)01 (0.6)00 Noncardiac chest pain1 (0.6)01 (0.6)00 Pleuritic pain1 (0.6)01 (0.6)00 Proteinuria1 (0.6)01 (0.6)00 Pulmonary arterial hypertension1 (0.6)01 (0.6)00 Respiratory distress1 (0.6)0001 (0.6) Respiratory failure1 (0.6)001 (0.6)0*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *GGT* γ-glutamyl transferase

Of eight patients (4.8%) who discontinued avelumab because of a treatment-related AE, three (1.8%) discontinued because of an immune-related AE (autoimmune hepatitis \[*n* = 2, both grade 3\] and pemphigoid \[*n* = 1, grade 2\]); other treatment-related AEs resulting in discontinuation were elevated γ-glutamyl transferase (*n* = 2, grades 3 and 4), elevated aspartate aminotransferase (*n* = 1, grade 3), elevated creatine phosphokinase (*n* = 1, grade 1), and respiratory distress (*n* = 1, grade 5). Two patients (1.2%) had a treatment-related death, including the patient with acute liver failure described above and a patient with metastatic lesions of liver, lung, and soft tissues and a history of respiratory disorders (cough, dyspnea, and pneumonia) who died of respiratory distress. The patient with treatment-related respiratory distress also presented with unspecified sepsis, most likely secondary to healthcare-associated pneumonia, and extensive pulmonary metastasis.

Antitumor activity {#Sec9}
------------------

Based on investigator assessment, five patients had a confirmed objective response, including one complete response and four partial responses, resulting in a confirmed ORR of 3.0% (95% CI 1.0--6.8; Table [3](#Tab3){ref-type="table"}). Notably, three of five confirmed responders (60.0%) had TNBC, resulting in an ORR of 5.2% in this subset (Appendix Table [9](#Tab9){ref-type="table"}). The other two confirmed responders had HER2− ER/PR+ disease, and the ORR in this subset was 2.8% (Appendix Table [9](#Tab9){ref-type="table"}). Four out of five responses were ongoing at data cutoff, and median duration of response was not reached (95% CI 28.7, ne). The unconfirmed ORR in the total population was 4.8%, including one complete response and seven partial responses, and the median time to response was 11.4 weeks (range 5.7--17.6 weeks) (Fig. [1](#Fig1){ref-type="fig"}). Stable disease was the best response in 42 patients (25.0%), and the disease control rate (DCR)---based on patients with a confirmed response or stable disease---was 28.0% (47 of 168) (Table [3](#Tab3){ref-type="table"}). Within the TNBC subgroup, 15 patients (25.9%) had stable disease as best response, and the DCR was 31.0% (18 of 58). Of the 47 patients with a best response of complete response, partial response, or stable disease, 14 (29.8%) remained progression free for ≥ 24 weeks.Table 3Antitumor activity of avelumabStudy population *N* = 168TNBC subgroup *n* = 58Complete response, *n* (%)1 (0.6)0Partial response, *n* (%)4 (2.4)3 (5.2)Stable disease,^a^ *n* (%)42 (25.0)15 (25.9)Progressive disease, *n* (%)106 (63.1)38 (65.5)Nonevaluable,^b^ *n* (%)15 (8.9)2 (3.4)ORR (95% CI) (%)3.0 (1.0 to 6.8)5.2 (1.1 to 14.4)DCR (%)28.031.0Median (95% CI) duration of response in confirmed responders (weeks)ne (28.7 to ne)ne (ne to ne)Median (95% CI) progression-free survival (weeks)5.9 (5.9 to 6.0)5.9 (5.7 to 6.9)Progression-free survival rate at 24 weeks (95% CI) (%)10.1 (5.9 to15.5)12.4 (5.2 to 22.8)Median (95% CI) overall survival (months)8.1 (6.4 to ne)9.2 (4.3 to ne)Overall survival rate at 12 months (95% CI) (%)40.3 (29.6 to 50.7)37.1 (18.3 to 56.2)Treatment responses are based on confirmed response according per Response Criterion In Solid Tumors version 1.1*DCR* disease control rate (defined as responses + stable disease), *ne* not estimable, *ORR* objective response rate^a^Stable disease at the first post-baseline tumor assessment after 6 weeks was required to qualify for a best response of SD^b^Includes "missing" and "not assessable" Fig. 1Time to and duration of response for patients with confirmed or unconfirmed responses

Of 140 patients who had evaluable data for sum of target lesion diameter at baseline and on study, 39 patients (27.9%) experienced tumor shrinkage of any level. Sixteen (11.4%) of these patients had tumor shrinkage of ≥ 30%, including two patients with progressive disease by RECIST who had a partial response by modified immune-related response criteria (Fig. [2](#Fig2){ref-type="fig"}). Among 46 evaluable patients with TNBC, 21 (45.7%) had tumor shrinkage of any level, which was by ≥ 30% in ten patients (21.7%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Best change in target lesions from baseline in 140 evaluable patients with baseline tumor assessment and ≥ 1 post-baseline assessment Fig. 3Percent change in target lesions from baseline in 46 evaluable patients with TNBC with baseline tumor assessment and ≥ 1 post-baseline assessment

No trends for response were observed based on patient or disease characteristics, including age, race, ECOG status, and prior lines of therapy (Appendix Table [9](#Tab9){ref-type="table"}). In addition, no efficacy trends were seen in subgroups defined by PD-L1 expression in tumor cells at different thresholds (Appendix Table [10](#Tab10){ref-type="table"}). However, in evaluable patients with PD-L1+ or PD-L1− tumor-associated immune cells (10% staining cutoff), the ORR was 16.7% (2 of 12 patients) versus 1.6% (2 of 124 patients) in the overall group, and 22.2% (2 of 9 patients) versus 2.6% (1 of 39 patients) in patients with TNBC.

Discussion {#Sec10}
==========

In this study of 168 heavily pretreated patients with MBC refractory to or progressing after standard-of-care therapy, avelumab monotherapy showed an acceptable safety profile with an incidence of grade ≥ 3 treatment-related AEs (13.7%) comparable with other anti-PD-L1/PD-1 therapies in MBC \[[@CR17], [@CR18]\]. Antitumor activity was modest, with a confirmed ORR of 3.0% based on one complete response and four partial responses. Of these five responders, three were in the TNBC subgroup (ORR 5.2%). Importantly, responses were durable, and the median duration of response was not reached during available follow-up. Tumor shrinkage occurred in 27.9% of evaluable patients in the overall MBC group and in 45.7% of patients with TNBC. The DCR was 28.0% in the total patient group and 31.0% in patients with TNBC. Preclinical studies suggest that avelumab may mediate tumor lysis through ADCC, indicating the presence of a potential second mechanism of action \[[@CR21]--[@CR23]\]. However, no clinical data are available to show that ADCC contributes to the clinical activity of avelumab. Importantly, the frequency of immune cell subsets is not decreased following treatment with avelumab \[[@CR29]\].

To date, the use of PD-L1 as a predictive biomarker for MBC remains controversial given the use of different PD-L1 antibodies and detection assays, various PD-L1 expression cutoffs, and non-standardized test designs \[[@CR30], [@CR31]\]. Studies of pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) have included analyses of tumor PD-L1 expression in patients with TNBC \[[@CR17], [@CR19]\]. In the phase 1b KEYNOTE-012 study of pembrolizumab in PD-L1+ TNBC (*n* = 27 evaluable patients), PD-L1 positivity was defined as expression in the stroma or in ≥ 1% of tumor cells based on IHC staining using the 22C3 PD-L1 antibody. In this PD-L1+ cohort, the ORR was 18.5%, 37.5% of evaluable patients had tumor shrinkage of any level, and the DCR was 25.9% \[[@CR17]\]. An exploratory analysis suggested an association between PD-L1 score (percentage of inflammatory and tumor cells staining for PD-L1) and the probability of response and progression-free survival with pembrolizumab. Similarly, in a phase 1a study of atezolizumab in 115 patients with heavily pretreated TNBC, of whom 71 were PD-L1+ (based on ≥ 5% of tumor-infiltrating immune cells \[IHC score of 2/3 using the SP142 assay\]) and were considered evaluable for efficacy, the unconfirmed ORR was 13% \[[@CR19]\]. In our study, a possible trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1− tumor-associated immune cells, both in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%). The response rate to avelumab in patients with TNBC and PD-L1+ tumor-associated immune cells is comparable with the response rate of 18.5 and 13% reported for patients with PD-L1+ TNBC treated with pembrolizumab and atezolizumab, respectively \[[@CR17], [@CR19]\]. Although the small number of evaluable patients with PD-L1+ TILs in our study (*n* = 12) precludes any definitive conclusions, these data support the hypothesis that PD-L1 expression on TILs may predict response to checkpoint inhibitor therapy in breast cancer. In our study, unlike in the pembrolizumab and atezolizumab studies, PD-L1 expression was evaluated separately in tumor cells and tumor-associated immune cells as prespecified in the analysis plan, and the Dako PD-L1 IHC 73-10 pharmDx assay was used for the evaluation. Efforts to standardize testing for PD-L1 expression are underway, including the Blueprint PD-L1 IHC comparison project \[[@CR32]\]. Data are not yet available to compare the performance of the 73-10 assay with that of other assays, although studies are ongoing, and the 73-10 assay will be included in phase 2 of the Blueprint study. Studies to characterize the potential of PD-L1 as a predictive biomarker for avelumab are ongoing.

In conclusion, our data show that the anti-PD-L1 antibody avelumab has a safety profile that is considered generally manageable and tolerable, and showed modest clinical activity in a heavily pretreated population of patients with MBC. Collectively, our findings and those of other studies suggest that durable clinical benefit can be achieved with anti-PD-1/PD-L1 monotherapy in a subset of patients with MBC, particularly TNBC \[[@CR17]--[@CR19]\]. Based on the results from single-agent immunotherapy in patients with MBC, studies of combination therapy that might increase the probability of treatment benefit are warranted, and promising clinical activity in TNBC has been reported for a treatment regimen of atezolizumab administered in combination with taxane chemotherapy (NCT01633970) and of pembrolizumab in combination with eribulin mesylate (NCT02513472) in preliminary studies \[[@CR33], [@CR34]\]. An ongoing phase 1b/2 study (JAVELIN Medley; NCT02554812), which includes a TNBC cohort, is currently assessing avelumab in combination with novel immunotherapies.

Appendix {#Sec11}
========

See Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, and [10](#Tab10){ref-type="table"}.Table 4Additional patient demographics and disease characteristicsCharacteristics, *n* (%)*N* = 168Prior surgery161 (95.8)Prior radiotherapy139 (82.7)Prior anticancer therapies in any setting 15 (3.0) 227 (16.1) ≥ 3136 (80.9)Median (range)4.0 (1--10)Prior platinum regimen Carboplatin based36 (21.4) Cisplatin based9 (5.4)Type of prior anticancer therapy Chemotherapy168 (100.0) Hormonal therapy103 (61.3) Antibody therapy30 (17.9) Kinase inhibitor19 (11.3) Vaccines1 (0.6) Other36 (21.4)Intent of any prior therapy Neoadjuvant64 (38.1) Adjuvant111 (66.1) Metastatic137 (81.5) Locally advanced30 (17.9) Palliative7 (4.2)Best response to any prior anticancer therapy Complete response3 (1.8) Partial response9 (5.4) Stable disease33 (9.6) Progressive disease94 (56.0) Not assessable1 (0.6) Unknown13 (7.7) Not applicable15 (8.9) Table 5Key eligibility criteriaInclusion criteriaExclusion criteriaAge ≥ 18 yearsPrior therapy with any drug targeting T cell coregulatory proteinsHistologically confirmed MBC that is refractory to or progressive after standard-of-care therapyConcurrent anticancer therapy within 4 weeks of start of trial treatment, use of hormonal agents within 7 days of start of trial treatment, or any other concurrent investigational treatmentNo more than three prior lines of cytotoxic therapy for metastatic diseasePrior treatment with immunosuppressive agents such as steroidsPrior treatment with a taxane and an anthracycline, unless contraindicatedMajor surgery ≤ 4 weeks prior to enrollmentAvailability of a formalin-fixed, paraffin-embedded block containing tumor tissue or unstained tumor slides suitable for PD-L1 expression assessmentPrevious malignant disease other than MBC within the last 5 years except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situECOG performance status score of 0 or 1Metastases of the central nervous systemMeasurable disease by RECIST version 1.1 or objective evidence of disease without a measurable lesionClinically significant illness, including infection, autoimmune disease (other than diabetes mellitus type 1, vitiligo, psoriasis, hypothyroid disease, or hyperthyroid disease not requiring immunosuppressive treatment), cardiovascular disease, or a psychiatric condition affecting the understanding or rendering of informed consentEstimated life expectancy of ≥ 3 monthsPersisting toxicity of grade \> 1 related to prior therapy (except grade ≤ 2 sensory neuropathy)Adequate renal, hepatic, and hematologic functionKnown severe hypersensitivity to monoclonal antibodies, history of anaphylaxis, or uncontrolled asthmaUse of highly effective contraceptionVaccination (other than inactivated vaccines) within 55 days of the first dose of avelumabSigned written informed consentPregnancy or lactationKnown alcohol or drug abuseLegal incapacity or limited legal capacity*ECOG* Eastern Cooperative Oncology Group, *MBC* metastatic breast cancer, *PD*-*L1* programmed death-ligand 1, *RECIST* Response Evaluation Criteria In Solid Tumors Table 6Prior cytotoxic therapiesTherapyPatients (*N* = 168)Cyclophosphamide132 (78.6)Paclitaxel108 (64.3)Doxorubicin94 (56.0)Docetaxel86 (51.2)Capecitabine79 (47.0)Fluorouracil38 (22.6)Carboplatin36 (21.4)Epirubicin34 (20.2)Trastuzumab30 (17.9)Bevacizumab29 (17.3)Everolimus26 (15.5)Nab-paclitaxel24 (14.3)Gemcitabine19 (11.3)Gemcitabine hydrochloride17 (10.1)Eribulin16 (9.5)Pegylated liposomal doxorubicin hydrochloride16 (9.5)Methotrexate12 (7.1)Vinorelbine tartrate10 (6.0)Cyclophosphamide with doxorubicin9 (5.4)Lapatinib7 (4.2)Pertuzumab7 (4.2)Cisplatin6 (3.6)Trastuzumab emtansine6 (3.6)Vinorelbine6 (3.6)Eribulin mesylate3 (1.8)Ixabepilone3 (1.8)Cisplatin with docetaxel2 (1.2)Cyclophosphamide with docetaxel/doxorubicin2 (1.2)Cyclophosphamide with epirubicin hydrochloride/fluorouracil2 (1.2)Cyclophosphamide with fluorouracil/methotrexate2 (1.2)Doxorubicin hydrochloride2 (1.2)Onartuzumab2 (1.2)Veliparib2 (1.2)PI3 kinase inhibitor2 (1.2)Doxorubicin/cyclophosphamide and paclitaxel1 (0.6)Carboplatin with gemcitabine1 (0.6)Cetuximab1 (0.6)5-Fluorouracil, epirubicin, and cyclophosphamide1 (0.6)Cyclophosphamide with epirubicin/fluorouracil1 (0.6)Epirubicin hydrochloride1 (0.6)Idarubicin1 (0.6)Irinotecan1 (0.6)Lapatinib ditosylate monohydrate1 (0.6)Neratinib1 (0.6)Olaparib1 (0.6)Panitumumab1 (0.6)Ruxolitinib1 (0.6)Sorafenib1 (0.6) Table 7Adverse events (related or unrelated) of any grade in \> 5% of patients or of grade ≥ 3 in any patientAdverse event, *n* (%)Patients (*N* = 168)Any gradeGrade 1Grade 2Grade 3Grade 4Grade 5Any event, *n* (%)161 (95.8)24 (14.3)57 (33.9)48 (28.6)10 (6.0)22 (13.1)Fatigue63 (37.5)30 (17.9)30 (17.9)3 (1.8)00Nausea49 (29.2)29 (17.3)19 (11.3)1 (0.6)00Constipation29 (17.3)21 (12.5)8 (4.8)000Decreased appetite29 (17.3)19 (11.3)10 (6.0)000Diarrhea29 (17.3)22 (13.1)7 (4.2)000Vomiting25 (29.2)14 (8.3)9 (5.4)2 (1.2)00Back pain24 (14.3)10 (6.0)7 (4.2)7 (4.2)00Cough24 (14.3)19 (11.3)5 (3.0)000Dyspnea24 (14.3)10 (6.0)4 (2.4)9 (5.4)1 (0.6)0Infusion-related reaction24 (14.3)6 (3.6)18 (10.7)000Arthralgia23 (13.7)15 (8.9)3 (1.8)5 (3.0)00Dyspnea exertional23 (13.7)15 (8.9)6 (3.6)1 (0.6)1 (0.6)0Pyrexia21 (12.5)18 (10.7)2 (1.2)1 (0.6)00Abdominal pain19 (11.3)11 (6.5)5 (3.0)3 (1.8)00Abdominal pain upper19 (11.3)7 (4.2)11 (6.5)1 (0.6)00Anemia17 (10.1)2 (1.2)5 (3.0)9 (5.4)1 (0.6)0Pleural effusion17 (10.1)4 (2.4)4 (2.4)8 (4.8)1 (0.6)0Urinary tract infection17 (10.1)5 (3.0)12 (7.1)000Asthenia16 (9.5)7 (4.2)6 (3.6)3 (1.8)00Edema peripheral15 (8.9)8 (4.8)6 (3.6)1 (0.6)00Headache15 (8.9)13 (7.7)2 (1.2)000Elevated AST14 (8.3)2 (1.2)6 (3.6)6 (3.6)00Influenza-like illness14 (8.3)13 (7.7)1 (0.6)000Pain in extremity13 (7.7)5 (3.0)5 (3.0)3 (1.8)00Disease progression12 (7.1)001 (0.6)1 (0.6)10 (6.0)Musculoskeletal pain12 (7.1)4 (2.4)8 (4.8)000Noncardiac chest pain12 (7.1)4 (2.4)3 (1.8)5 (3.0)00Abdominal distension11 (6.5)6 (3.6)4 (2.4)1 (0.6)00Anxiety11 (6.5)6 (3.6)5 (3.0)000Decreased weight11 (6.5)7 (4.2)4 (2.4)000Dizziness11 (6.5)7 (4.2)3 (1.8)1 (0.6)00Elevated ALT11 (6.5)6 (3.6)4 (2.4)1 (0.6)00Hypertension11 (6.5)4 (2.4)5 (3.0)2 (1.2)00Insomnia11 (6.5)6 (3.6)5 (3.0)000Musculoskeletal chest pain11 (6.5)7 (4.2)3 (1.8)1 (0.6)00Hypothyroidism10 (6.0)2 (1.2)8 (4.8)000Muscle spasms10 (6.0)10 (6.0)0000Neck pain10 (6.0)4 (2.4)6 (3.6)000Dry skin9 (5.4)8 (4.8)1 (0.6)000Hypokalemia9 (5.4)3 (1.8)5 (3.0)01 (0.6)0Pruritus9 (5.4)7 (4.2)2 (1.2)000Chest pain8 (4.8)5 (3.0)2 (1.2)1 (0.6)00Elevated blood alkaline phosphatase7 (4.2)2 (1.2)3 (1.8)2 (1.2)00Myalgia7 (4.2)6 (3.6)01 (0.6)00Elevated GGT6 (3.6)1 (0.6)1 (0.6)2 (1.2)2 (1.2)0Flank pain5 (3.0)2 (1.2)2 (1.2)1 (0.6)00Hyponatremia5 (3.0)2 (1.2)1 (0.6)2 (1.2)00Hypoxia5 (3.0)03 (1.8)2 (1.2)00Pneumonia5 (3.0)01 (0.6)4 (2.4)00Hypercalcemia4 (2.4)2 (1.2)1 (0.6)01 (0.6)0Thrombocytopenia4 (2.4)1 (0.6)003 (1.8)0Respiratory failure4 (2.4)0002 (1.2)2 (1.2)Autoimmune hepatitis3 (1.8)003 (1.8)00Axillary pain3 (1.8)1 (0.6)1 (0.6)1 (0.6)00General physical health deterioration3 (1.8)002 (1.2)01 (0.6)Hyperglycemia3 (1.8)02 (1.2)1 (0.6)00Lymphocyte count decreased3 (1.8)02 (1.2)1 (0.6)00Metastatic pain3 (1.8)1 (0.6)02 (1.2)00Pleuritic pain3 (1.8)1 (0.6)1 (0.6)1 (0.6)00Pneumonitis3 (1.8)1 (0.6)1 (0.6)1 (0.6)00Pneumothorax3 (1.8)1 (0.6)1 (0.6)1 (0.6)00Proteinuria3 (1.8)2 (1.2)01 (0.6)00Sinus tachycardia3 (1.8)1 (0.6)1 (0.6)1 (0.6)00Atrial fibrillation2 (1.2)001 (0.6)1 (0.6)0Cardiac tamponade2 (1.2)001 (0.6)1 (0.6)0Deep vein thrombosis2 (1.2)01 (0.6)1 (0.6)00Hematuria2 (1.2)1 (0.6)01 (0.6)00Hepatomegaly2 (1.2)1 (0.6)01 (0.6)00Hypophosphatemia2 (1.2)002 (1.2)00International normalized ratio increased2 (1.2)1 (0.6)01 (0.6)00Jugular vein thrombosis2 (1.2)002 (1.2)00Metastases to meninges2 (1.2)01 (0.6)01 (0.6)0Neutrophil count decreased2 (1.2)1 (0.6)01 (0.6)00Platelet count decreased2 (1.2)01 (0.6)1 (0.6)00Radiation pneumonitis2 (1.2)1 (0.6)01 (0.6)00Rash papular2 (1.2)1 (0.6)01 (0.6)00Respiratory distress2 (1.2)001 (0.6)01 (0.6)Acute hepatic failure1 (0.6)00001 (0.6)Acute kidney injury1 (0.6)001 (0.6)00Ataxia1 (0.6)001 (0.6)00Bile duct obstruction1 (0.6)001 (0.6)00Brain injury1 (0.6)00001 (0.6)Bronchial obstruction1 (0.6)001 (0.6)00Burning sensation1 (0.6)001 (0.6)00Cardiac arrest1 (0.6)0001 (0.6)0Cardiac failure1 (0.6)0001 (0.6)0Cardio-respiratory arrest1 (0.6)00001 (0.6)Cellulitis1 (0.6)001 (0.6)00Cholestasis1 (0.6)001 (0.6)00Coccydynia1 (0.6)001 (0.6)00Dental caries1 (0.6)001 (0.6)00Electrocardiogram QT prolonged1 (0.6)001 (0.6)00Elevated blood potassium1 (0.6)001 (0.6)00Elevated hepatic enzyme1 (0.6)001 (0.6)00Failure to thrive1 (0.6)001 (0.6)00Hemoptysis1 (0.6)001 (0.6)00Hepatic encephalopathy1 (0.6)0001 (0.6)0Hepatic failure1 (0.6)00001 (0.6)Hyperbilirubinemia1 (0.6)001 (0.6)00Hypercalcemia of malignancy1 (0.6)0001 (0.6)0Hypertriglyceridemia1 (0.6)001 (0.6)00Infection1 (0.6)001 (0.6)00Liver disorder1 (0.6)001 (0.6)00Malignant neoplasm progression1 (0.6)00001 (0.6)Malignant pleural effusion1 (0.6)001 (0.6)00Malnutrition1 (0.6)001 (0.6)00Metastases to peripheral nervous system1 (0.6)0001 (0.6)0Monoparesis1 (0.6)001 (0.6)00Myelodysplastic syndrome1 (0.6)0001 (0.6)0Neutropenia1 (0.6)0001 (0.6)0Obstructive uropathy1 (0.6)001 (0.6)00Pain in hip, back, and right lower leg1 (0.6)001 (0.6)00Paraparesis1 (0.6)0001 (0.6)0Pathological fracture1 (0.6)001 (0.6)00Pleural fistula1 (0.6)001 (0.6)00Pulmonary arterial hypertension1 (0.6)001 (0.6)00Pulmonary embolism1 (0.6)00001 (0.6)Pulmonary hypertension1 (0.6)00001 (0.6)Sepsis1 (0.6)00001 (0.6)Spinal cord compression1 (0.6)001 (0.6)00Tumor invasion1 (0.6)00001 (0.6)Tumor pain1 (0.6)001 (0.6)00*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *GGT* γ-glutamyl transferase Table 8Potential immune-related, treatment-related adverse events by gradeAdverse event, *n* (%)Patients (*N* = 168)Any gradeGrade 1Grade 2Grade 3Grade 4Grade 5Any event, *n* (%)**17 (10.1)4 (2.4)9 (5.4)3 (1.8)1 (0.6)0**Hypothyroidism8 (4.8)1 (0.6)7 (4.2)000Autoimmune hepatitis^a^3 (1.8)003 (1.8)00Pneumonitis3 (1.8)1 (0.6)1 (0.6)1 (0.6)00Thrombocytopenia2 (1.2)1 (0.6)001 (0.6)0ANA positive1 (0.6)1 (0.6)0000Dry eye1 (0.6)1 (0.6)0000Elevated rheumatoid factor1 (0.6)1 (0.6)0000Hyperthyroidism1 (0.6)1 (0.6)0000Pemphigoid^b^1 (0.6)01 (0.6)000The numbers in bold are the total number of immune related evens according to grade*ANA* antinuclear antibody^a^Autoimmune hepatitis temporarily resolved with steroid treatment, but led to discontinuation in two patients; the third patient who experienced autoimmune hepatitis died of acute liver failure in a setting of progressive liver metastasis^b^Pemphigoid resolved following drug interruption but ultimately led to treatment discontinuation Table 9Confirmed ORR by subgroupSubgroup*n*/*N*1ORR % (95% CI)Age (years) \< 654/1402.9 (0.8, 7.2) ≥ 651/283.6 (0.1, 18.3)Race White3/1432.1 (0.4, 6.0) Black2/258.0 (1.0, 26.0)ECOG 03/833.6 (0.8, 10.2) ≥ 12/852.4 (0.3, 8.2)Prior lines for metastatic disease^a^ ≤ 12/454.4 (0.5, 15.1) 22/355.7 (0.7,19.2) ≥ 31/881.1 (0, 6.2)Biomarker group TNBC3/585.2 (1.1, 14.4) HER2− (ER+ or PR+)2/722.8 (0.3, 9.7) HER2+0/260 (0, 13.2) Unknown^b^0/120 (0, 26.5)*ECOG PS* Eastern Cooperative Oncology Group performance status, *ER* estrogen receptor, *HER2* human epidermal growth factor receptor 2, *N1* number of evaluable patients, *ORR* objective response rate, *PR* progesterone receptor, *TNBC* triple-negative breast cancer, *N1* number of evaluable patients^a^Regimen for locally advanced/metastatic disease may have included hormonal therapy, either alone or in combination with chemotherapy. Systemic therapies that were not necessarily cytotoxic are included in the number of prior regimens reported here, but the number of cytotoxic therapies permitted was ≤ 3^b^ Unknown molecular subtype was due to incomplete information in the medical records database (ER/PR status known, but HER2 status unknown in four patients) or to information collected retrospectively (molecular subtype status was from post-baseline samples in eight patients and, therefore, was not used for baseline characterization Table 10Confirmed response, progression-free survival, and overall survival in patient subgroups defined by PD-L1 expression in tumor or immune cellsPD-L1+PD-L1−*P* value^a^Hazard ratio (95% CI)≥ 1% Tumor cells, any intensity Prevalence, *n*8551---- ORR (95% CI), *n*/*N*1 (%)2/85 (2.4 \[0.3, 8.2\])2/51 (3.9 \[0.5, 13.5\])0.631-- Median PFS (95% CI) (weeks)5.9 (5.7, 6.0)6.0 (5.9, 6.0)--1.183 (0.815, 1.716) PFS rate at 24 weeks (95% CI) (%)6.2 (2.1, 13.6)12.8 (5.3, 23.8)-- Median OS (95% CI) (months)6.5 (3.7, 9.2)8.3 (6.3, ne)--1.331 (0.815, 2.174) OS rate at 12 months (95% CI) (%)35.6 (24.2,47.1)36.8 (14.8, 59.3)--≥ 5% Tumor cells, any intensity Prevalence, *n*23113---- ORR (95% CI), *n*/*N*1 (%)1/23 (4.3 \[0.1, 21.9\])3/113 (2.7 \[0.6, 7.6\])0.528-- Median PFS (95% CI) (weeks)6.0 (5.7, 7.1)5.9 (5.9, 6.0)--0.782 (0.473, 1.290) PFS rate at 24 weeks (95% CI) (%)15.5 (3.3, 36.0)7.7 (3.6, 13.8)-- Median OS (95% CI) (months)6.5 (2.2, ne)7.5 (5.1, 11.3)--1.057 (0.556, 2.010) OS rate at 12 months (95% CI) (%)ne35.9 (23.7, 48.2)--≥ 25% Tumor cells, high intensity (≥ 2+) Prevalence, *n*3133---- ORR (95% CI), *n*/*N*1 (%)0/3 (0 \[0, 70.8\])4/133 (3.0 \[0.8,7.5\])1.000-- Median PFS (95% CI) (weeks)6.0 (5.4, ne)5.9 (5.9, 6.0)--0.695 (0.172, 2.813) PFS rate at 24 weeks (95% CI) (%)ne8.6 (4.5, 14.5)-- Median OS (95% CI) (months)9.2 (ne, ne)6.8 (4.9, 10.8)--0.441 (0.061, 3.177) OS rate at 12 months (95% CI) (%)0 (ne, ne)36.3 (25.0, 47.6)--≥ 10% Tumor-associated immune cells, any intensity Prevalence, *n*12124---- ORR (95% CI), *n*/*N*1 (%)2/12 (16.7 \[2.1, 48.4\])2/124 (1.6 \[0.2, 5.7\])0.039-- Median PFS (95% CI) (weeks)6.1 (2.3, 24,1)5.9 (5.9, 6.0)--0.656 (0.341, 1.263) PFS rate at 24 weeks (95% CI) (%)25.0 (6.0, 50.5)7.0 (3.2, 12.9)-- Median OS (95% CI) (months)11.3 (1.4, ne)6.8 (4.7, 9.2)--0.620 (0.250, 1.541) OS rate at 12 months (95% CI) (%)33.3 (1.7, 74.4)37.4 (27.4, 47.4)--*ne* not estimable, *N1* number of patients with evaluable PD-L1 expression, *ORR* objective response rate, *OS* overall survival, *PD*-*L1* programmed death-ligand 1, *PFS* progression-free survival^a^Fisher's exact test
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